GENETIC TECHNOLOGIES LIMITED — Investor Presentation 2010

Nov 23, 2010

==> picture [595 x 72] intentionally omitted <==

==> picture [595 x 72] intentionally omitted <==

ASX ANNOUNCEMENT November 24[th] , 2010

2010 Annual General Meeting

Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) is pleased to release the attached slide show presentation which will be delivered by Chief Executive Officer, Dr. Paul MacLeman, at the Company’s 2010 Annual General Meeting to be held at 10.00 am this morning in the “Treetops” Room at Melbourne Museum, 11 Nicholson Street, Carlton, Victoria, Australia.

FOR FURTHER INFORMATION PLEASE CONTACT

Thomas G. Howitt Company Secretary

Genetic Technologies Limited (ABN 17 009 212 328) Telephone: +61 3 8412 7000

Genetic Technologies Limited • Website : www.gtglabs.com • Email : info@gtglabs.com ABN 17 009 212 328 Registered Office • 60-66 Hanover Street Fitzroy Victoria 3065 Australia • Postal Address P.O. Box 115 Fitzroy Victoria 3065 Australia Phone +61 3 8412 7000 • Fax +61 3 8412 7040

Annual General Meeting

Dr Paul MacLeman, CEO TreeTops, Melbourne Museum, November 24, 2010

Forward looking statements

This presentation may contain forward‐looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933 and Section 21E of the U.S. Securities Exchange Act of 1934 with respect to the financial condition, results and business achievements/performance of Genetic Technologies Limited and certain of the plans and objectives of its management. These statements are statements that are not historical facts. Words such as “should”, “expects”, “anticipates”, “estimates”, “believes” or similar expressions, as they relate to Genetic Technologies Limited, are intended to identify forward‐looking statements. By their nature, forward‐looking statements involve risk and uncertainty because they reflect Genetic Technologies’ current expectations and assumptions as to future events and circumstances that may not prove accurate. There is no guarantee that the expected events, trends or results will actually occur. Any changes in such assumptions or expectations could cause

Your Company

� Back to basics approach to growing our business

• More products in more territories

• Reduced costs

• Strategy for meaningful growth and profitability

• Focused on a few measurable, deliverable milestones

Today’s Presentation

� Review of last year’s objectives

� Progress towards these objectives

• Goals for this year

2010 Goals and Outcomes

Medical		Animal		Profiling
�Leading provider of cancer management tools, Asia Pacific �Global relationships or M&A accessing leading products	� �	�Leading provider of breeding health management �Expand into household, veterinary and pedigree channels	� �	�Leading private provider in the region �Commercial solutions for law enforcement and immigration	� �

�

Licensing Program: Resources for Growth

�World class in‐house licensing team	Parties joined suit #1:
�Partnership with Sheridan Ross PC, a full service intellectual property law firm based in Colorado	�settled �Beckman Coulter �Orchid Cellmark �Gen‐Probe
�9 assertion candidates joined to first assertion � (5 settled, 3 in settlement negotiations)	�Interleukin Genetics �Molecular Pathology Laboratory Network
�Delivering results, in addition we have had wins	�Monsanto �PIC USA
in Europe outside this program	�Sunrise Medical
�Off balance sheet financing	Laboratories �Pioneer Hi‐Bred

Australian Operations

• Sales increases, examples

• Royal Women's Hospital

• Royal North Shore Hospital

• Chinese Kennel Union

• Service, price and competency

• Cost containment

• Head count 85 to 58 last 12mm

• Divestment non‐productive assets

Medical Strategy Delivers Early Results

Planned Q1 2011 launch

Compelling Market Opportunity

• The US market for existing breast cancer molecular diagnostics is approximately $690MM*

• Referenced by:

• BRACAnalysis (Myriad) sales

  • ~$320MM in 7 years

• OncotypeDx (Genomics Health)

• ~$200MM in 5 years

• Other players (Genzyme, Clarient, etc.) make up the balance

• BREVAGen™ target US market is a patient population of 1,000,000

BREVAGen™ ‐ Nearing US Launch

Marketing via subsidiary Phenogen Sciences Inc. (USA), GTG RoW

• Large global opportunity

• Preparing for staged US launch Q1 2011

• Unique, patented product

• Peer reviewed validation study Oct10 Journal of National Cancer Institutes

• � CLIA registration in train: Australia’s first globally accredited lab

BREVAGen™ Opportunity

Short Term

ADH/ ALH/ LCIS (400k) All Mammogram Targets (60.3M)**

Longer Term

*Estimate from PhenoGen Sciences

BREVAGen™ – World’s First Validated Non‐Familial Breast Cancer Test (85% of cases)

==> picture [301 x 30] intentionally omitted <==

----- Start of picture text -----

Gail Score
----- End of picture text -----

1.6 million breast biopsies per year (USA) �

Financials

Improvements in both product Cost reductions and rising and more strongly, in licensing revenues have produced a revenues strong trend towards positive cash flows and rofitabilit p y

2011 Goals

Global business

• Successful launch of BREVAGen™ in US (& EU)

• Partner with pharmaceutical companies for development of companion diagnostics

Australian operations

• Move towards critical mass for Australian sales & operations

Business development and M&A

• Seek out other late stage product opportunities to market in US & Europe

• Look for win‐win partnerships

Summar y

� Genetic Technologies is becoming a leading global provider of cancer management tools

• BREVAGen™ the 1[st] in global portfolio

• New products, customers and revenues delivered to plan

• Revenue up, costs down, moving closer to profitability & meeting milestones

• Experienced management achieving goals

• US assertion and EU licensing strategy providing

Genetic Technologies Ltd

Taking Our Products to the World

Thank You

Dr Paul D R MacLeman CEO Genetic Technologies Ltd Phone +61 3 8412 7000 Cell +61 419 401 445 Email paul.macleman@gtglabs.com